REM-422 is under clinical development by Remix Therapeutics and currently in Phase I for Adenoid Cystic Carcinoma (ACC). According to GlobalData, Phase I drugs for Adenoid Cystic Carcinoma (ACC) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the REM-422 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

REM-422 overview

REM-422 is under development for the treatment of recurrent or metastatic adenoid cystic carcinoma (ACC) and acute myeloid leukemia (AML). The therapeutic candidate is administered through oral route as capsules. It acts by targeting the transcriptional activator MYB and is being developed based on REMaster platform technology.

Remix Therapeutics overview

Remix Therapeutics (Remix) is a biotechnology company that develops small molecule therapies for the treatment of cancer, genetic disorders and central nervous system diseases. The company focuses on altering the way genes are read from the genome to correct and enhance the gene message. It utilizes REMaster platform that combines data analytics, high throughput screening technologies and next-generation chemistry to identify molecules. Remix uses small molecules to modulate RNA sequences and control gene expression. The company addresses undrugged disease drivers to develop new medicines for patients. It serves pharmaceutical and healthcare sectors. Remix is headquartered in Watertown, Massachusetts, the US.

For a complete picture of REM-422’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.